Article
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.
Leukemia & lymphoma - 1 Dec 2020
Roboz Gail J, Strickland Stephen A, Litzow Mark R, Dalovisio Andrew, Perl Alexander E, Bonifacio Gaetano, Haines Kelly, Barbera Alysha, Purkayastha Das, Sweet Kendra
Abstract excerpt
Approval of midostaurin, a multikinase inhibitor, in combination with chemotherapy for the treatment of adults with newly diagnosed FLT3 mutation-positive acute myeloid leukemia, was based on the phase 3 RATIFY trial results. RADIUS-X (NCT02624570) was an expanded access program providing access...
Topics
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Radius
- Staurosporine
- fms-Like Tyrosine Kinase 3